The COVID-19 pandemic highlighted the important link between research and clinical care and its impact on the timely development of much-needed antivirals for severe lung viral infections caused by seasonal viruses and emerging respiratory viral threats.
Towards this end, Synairgen is collaborating with the Clinical Trials Unit of the University of Southampton and Janssen on the UNIVERSAL study (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal trial), an observational study to explore and better
understand the varied nature of acute respiratory viral infection and recovery seen in patients admitted to hospital with respiratory symptoms.
As an observational study, no treatments are being investigated.